Drugs / Albinterferon Alfa-2b
Albinterferon Alfa-2b
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00724776 | Jul 2008 → Jul 2009 | chronic hepatitis C virus infection | Novartis | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00964665 | Jul 2009 → Nov 2010 | chronic hepatitis B virus infection | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00759200 | Oct 2008 → Dec 2010 | chronic hepatitis C virus infection | Novartis | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00411385 | Feb 2007 → Oct 2008 | chronic hepatitis C virus infection | Human Genome Sciences Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albinterferon alfa-2b | “Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.” PMID 20600017 ↗ Jul 20104“Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b” PMID 22863266 ↗ Mar 2012 |
| Known as | albIFN | “a phase 3 active-controlled study was conducted to assess the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of recombinant...” PMID 20600017 ↗ Jul 20102“This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients” NCT00724776 ↗ “Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b” PMID 22863266 ↗ Mar 2012 |
| Known as | Albinterferon | “Albinterferon is a fusion of albumin and interferon-α2b developed to improve the pharmacokinetics, convenience, and potential efficacy of interferon-α for the treatment of...” PMID 24995515 ↗ Jan 2015 |
| Modality | Protein / enzyme biologic | “a novel, long-acting, genetic fusion polypeptide of recombinant human albumin and interferon alfa-2b” PMID 20600017 ↗ Jul 2010 |
| Route | Subcutaneous | “open-label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 μg/wk, or albIFN 900 or 1200 μg every 2 weeks for 24 weeks” PMID 20600017 ↗ Jul 2010 |